Prova Education designs educational programs that address a broad spectrum of gaps in awareness, attitudes, skills, and competencies related to guideline-based care and evolving disease management options. Its mission is to serve as an innovative and relevant resource for clinical content that promotes change in practice and patient outcomes.
When to Screen for Cushing’s Syndrome: Smart & Strategic Screening Approaches
When to Screen for Cushing’s Syndrome: Smart & Strategic Screening Approaches
Cervical Cancer: HER2-Targeted ADCs – Current Status and Future Directions
Cervical Cancer: HER2-Targeted ADCs – Current Status and Future Directions
Biliary Tract and Pancreatic Cancer: HER2-Targeted ADCs for Gastrointestinal Cancers
Biliary Tract and Pancreatic Cancer: HER2-Targeted ADCs for Gastrointestinal Cancers
Management Strategies for Treatment-Emergent Adverse Events (TEAEs) in HER2-Altered Advanced Solid Tumors
Management Strategies for Treatment-Emergent Adverse Events (TEAEs) in HER2-Altered Advanced Solid Tumors
Endometrial Cancer: HER2-Targeted ADCs: A Promising Approach to Address Unmet Needs
Endometrial Cancer: HER2-Targeted ADCs: A Promising Approach to Address Unmet Needs
ASCO/ESMO 2023 Roundtable: Contextualizing the Latest Advances in HER2-Targeted Therapy for Solid Tumors
ASCO/ESMO 2023 Roundtable: Contextualizing the Latest Advances in HER2-Targeted Therapy for Solid Tumors
Addressing the Unmet Need in HER2-Positive Advanced Solid Tumors: Exploring Response Rates and Duration of Response
Addressing the Unmet Need in HER2-Positive Advanced Solid Tumors: Exploring Response Rates and Duration of Response
Ovarian Cancer: Advances in HER2-Targeted ADCs
Ovarian Cancer: Advances in HER2-Targeted ADCs
Expanding Screening, Improving Treatment Acceptance, and Optimizing Outcomes for Patients with Moderate to Severe Alcohol Use Disorder (AUD)
Expanding Screening, Improving Treatment Acceptance, and Optimizing Outcomes for Patients with Moderate to Severe Alcohol Use Disorder (AUD)
Testing for Solid Tumors: Tissue and Liquid Biopsy Approaches Using NGS Technologies for cfDNA and ctDNA Analysis
Testing for Solid Tumors: Tissue and Liquid Biopsy Approaches Using NGS Technologies for cfDNA and ctDNA Analysis
Bladder Cancer: HER2-Targeted ADCs for Genitourinary Cancers
Bladder Cancer: HER2-Targeted ADCs for Genitourinary Cancers